RNS Number : 6083W
Spectral MD Holdings, Ltd.
19 August 2022
 

 

Spectral MD Holdings, Ltd

("Spectral MD" or the "Company" or the "Group") 

 

Grant of Options

 

LONDON, U.K AND DALLAS, TX, U.S. - Spectral MD Holdings, Ltd. (AIM: SMD), a predictive analytics company that develops proprietary AI algorithms and optical technology for faster and more accurate treatment decisions in wound care, announces that it has granted options ("Options") over a total of 1,080,000  common stock of US$0.001 ("Common Stock") in the Company ("Shares") to various new employees of the Company in accordance with the Company's 2018 Long Term Incentive Plan. The Options vest over a three-year period from the date of grant, expire after ten years and have an exercise price of 35.5 pence.

 

For further information, please contact:




Spectral MD Holdings, Ltd.

https://investors.spectralmd.com/

Wensheng Fan, Chief Executive Officer

Nils Windler, Chief Financial Officer

via Walbrook PR



SP Angel Corporate Finance LLP (Nominated Adviser and Joint Broker)

+44 (0) 20 3470 0470

Stuart Gledhill / Caroline Rowe (Corporate Finance)

Vadim Alexandre / Rob Rees (Sales and Corporate Broking)


Stifel Nicolaus Europe Limited (Joint Broker)

+44 (0) 20 7710 7600

Charles Hoare / Ben Maddison / Will Palmer-Brown




Walbrook PR Ltd (Media & Investor Relations)

+44 (0)20 7933 8780 or spectralMD@walbrookpr.com

Sam Allen / Alice Woodings

 

+44 (0)75 0255 8258 / +44 (0) 7407 804654

About Spectral MD:  

We are a dedicated team of forward-thinkers striving to revolutionize the management of wound care by "Seeing the Unknown" ® with our DeepView® Wound Imaging System.

www.spectralmd.com

info@spectralmd.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHGIGDIBBBDGDC